Klotho Neurosciences, Inc. (KLTO)

Klotho Neurosciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	0.06	0	0.08	0.3	0.33
Cash & Short-Term Investments	0.06	0	0.08	0.3	0.33
Cash Growth	2169.98%	-96.30%	-74.78%	-10.16%	47.29%
Receivables	-	-	0.25	-	-
Prepaid Expenses	0.09	0	0	0	-
Total Current Assets	0.16	0.01	0.33	0.3	0.33
Other Intangible Assets	2.3	2.19	2.21	0.74	0.74
Total Assets	2.46	2.19	2.54	1.04	1.07
Accounts Payable	0.06	0.15	0.01	0.02	-
Accrued Expenses	0.94	0.16	0	-	-
Short-Term Debt	0.24	1.31	1.35	-	-
Total Current Liabilities	1.25	1.62	1.36	0.02	-
Other Long-Term Liabilities	0.02	-	-	-	-
Total Liabilities	1.27	1.62	1.36	0.02	-
Common Stock	0	0	0.1	0.1	-
Additional Paid-In Capital	11.75	4.49	3.54	3.54	2.58
Retained Earnings	-10.56	-3.92	-3.22	-2.62	-1.51
Comprehensive Income & Other	-	-	0.75	-	-
Total Common Equity	1.19	0.57	1.18	1.03	1.07
Shareholders' Equity	1.19	0.57	1.18	1.03	1.07
Total Liabilities & Equity	2.46	2.19	2.54	1.04	1.07
Total Debt	0.24	1.31	1.35	-	-
Net Cash (Debt)	-0.18	-1.31	-1.27	0.3	0.33
Net Cash Growth	-	-	-	-10.16%	404.65%
Net Cash Per Share	-0.01	-0.09	-0.00	0.00	-
Filing Date Shares Outstanding	28.51	1,045	1,045	1,045	-
Total Common Shares Outstanding	27.08	1,045	1,045	1,045	-
Working Capital	-1.09	-1.61	-1.03	0.29	0.33
Book Value Per Share	0.04	0.00	0.00	0.00	-
Tangible Book Value	-1.11	-1.61	-1.03	0.29	0.33
Tangible Book Value Per Share	-0.04	-0.00	-0.00	0.00	-

Updated Nov 19, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q